Your shopping cart is currently empty

6RK73 is a covalent, irreversible, and specific UCHL1 inhibitor (IC50: 0.23 µM) with almost no inhibition of UCHL3 (IC50: 236 µM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | In Stock | In Stock | |
| 5 mg | $313 | In Stock | In Stock | |
| 10 mg | $537 | In Stock | In Stock | |
| 25 mg | $869 | In Stock | In Stock | |
| 50 mg | $1,190 | In Stock | In Stock | |
| 100 mg | $1,590 | In Stock | In Stock | |
| 500 mg | $3,220 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $345 | In Stock | In Stock |
| Description | 6RK73 is a covalent, irreversible, and specific UCHL1 inhibitor (IC50: 0.23 µM) with almost no inhibition of UCHL3 (IC50: 236 µM). |
| Targets&IC50 | UCHL3:236 µM , UCHL1:0.23 µM |
| In vitro | 6RK73 (5 µM; 1-3 hours) treatment displays strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels in MDA-MB-436 cells. 6RK73 (5 µM; 24-48 hours) results in migration significantly slower than the DMSO control group in MDA-MB-436 cells[1]. |
| In vivo | 6RK73 displays a potent inhibition of breast cancer extravasation in zebrafish[1]. |
| Cell Research | Cell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 24, 48 hours |
| Molecular Weight | 307.37 |
| Formula | C13H17N5O2S |
| Cas No. | 1895050-66-4 |
| Smiles | O=C(Nc1ncc(s1)N1CCOCC1)[C@H]1CCN(C1)C#N |
| Relative Density. | 1.41 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 112.5 mg/mL (366.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (13.01 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.